COSMETIC COMPOSITION COMPRISING AN ENDOLYSIN AND A POLYVINYL ALCOHOL
Polyvinyl alcohol (PVA) in cosmetic compositions with Staphylococcus aureus phage-derived endolysins maintains antimicrobial activity and specificity against Staphylococcus aureus, addressing stability issues in existing formulations.
Patent Information
- Application Number
- FR2024003985
- Authority / Receiving Office
- FR · FR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-04-17
- Publication Date
- 2024-11-29
AI Technical Summary
Existing cosmetic formulations using endolysins to target Staphylococcus aureus face stability issues, leading to degradation of antimicrobial activity over time, and there is a need for a film-forming and viscosity control agent that maintains this activity while preserving specificity for the target bacteria without degrading sensory properties.
Incorporating polyvinyl alcohol (PVA) into cosmetic compositions with endolysins derived from Staphylococcus aureus phages to maintain antimicrobial activity over several months.
PVA effectively preserves the antimicrobial performance of endolysins against Staphylococcus aureus, ensuring stability and specificity over extended periods, even in cosmetic formulations.
Abstract
Description
Title of the invention: COSMETIC COMPOSITION COMPRISING AN ENDOLYSIN AND A VINYL POLYALCOHOL Technical field
[0001] The present invention relates to a composition, in particular a cosmetic composition, comprising, in a physiologically acceptable medium, at least one endolysin, in particular an endolysin derived from a Staphylococcus aureus phage, and at least one polyvinyl alcohol.
[0002] The invention also relates in particular to the use of a composition of the invention for preventing and / or treating acne and / or eczema in an individual in need thereof.
[0003] Finally, the invention relates to a non-therapeutic cosmetic process for caring for keratinous materials, in particular the skin, comprising the topical application to these keratinous materials of a composition according to the invention. PREVIOUS ART
[0004] Human skin is permanently populated by a multitude of different microorganisms (bacteria, yeasts and fungi). The resident microbial flora, essential for good skin health, consists mainly of propionic bacteria (Cutibacterium acnes), staphylococci (Staphylococcus epidermidis and Staphylococcus hominis), corynebacteria and streptococci, as well as a fungal flora composed mainly of Malassezia.
[0005] Certain dermatological disorders are usually due to the disruption of the ecological balance of the resident flora following a predominant colonization of opportunistic microorganisms not beneficial for the skin, such as Staphylococcus aureus, known to be associated with atopic dermatitis (eczema), oily or hyperseborrheic skin, and acne.
[0006] To counter this excessive colonization by these opportunistic microorganisms that are not beneficial for the skin, it is common to use broad-spectrum antimicrobials or bacteriostatics. However, the use of these compounds poses the problem of the non-specificity of the action targeting both the undesirable opportunistic flora and the resident beneficial flora, and the problem of the risk of the appearance of resistance or bacterial imbalances by selecting resistant bacteria, but also of skin tolerance problems (irritation, allergies, etc.).
[0007] There is therefore a need to find new compounds having good antimicrobial efficacy, which do not have the aforementioned drawbacks and which have good skin tolerance.
[0008] It has thus been demonstrated that endolysins of Staphylococcus aureus phages (i.e. phages infecting Staphylococcus aureus) can specifically target S. aureus and lyse, and thus specifically destroy this bacterium while preserving the resident skin flora (WO 2012 / 150858). However, it is well known that one of the main obstacles to the application of endolysins targeting Staphylococcus species is a problem of stability of these proteins and / or their enzymatic activity, in particular the maintenance of this activity over time.
[0009] Indeed, it has been observed in particular that the lytic action of these enzymes is significantly altered by interactions with raw materials, in particular when endolysin is introduced into formulations, in particular cosmetic formulations.
[0010] There is therefore a need for a film-forming and / or viscosity-controlling agent which can be used in compositions, in particular cosmetic compositions, without degrading the antimicrobial activity of the endolysins also present in these compositions.
[0011] Furthermore, there is a need for a film-forming and / or viscosity-controlling agent that can be used in compositions, particularly cosmetic compositions, without degrading (i) the antimicrobial activity of the endolysins used and (ii) the specificity of these endolysins for the targeted bacteria, particularly in the present invention Staphylococcus aureus.
[0012] There is also a need for a film-forming and / or viscosity-controlling agent that can be used in compositions, particularly cosmetic compositions:
[0013] - without degrading the antimicrobial activity of the endolysins used;
[0014] - while retaining the specificity of these endolysins for the targeted bacteria, in particularly Staphylococcus aureus in the present invention; and
[0015] - while providing good sensory properties for the composition. DISCLOSURE OF THE INVENTION
[0016] The aim of the present invention is to solve at least one aforementioned technical problem.
[0017] Indeed, the inventors have now discovered that a polyvinyl alcohol (PVA) polymer, compared to other film-forming and / or viscosity-controlling agents known in the field of formulation, in particular cosmetic formulation, proves capable of maintaining good destruction performance of a endolysin, particularly an endolysin from Staphylococcus aureus, several months after the preparation of the composition. Summary of the invention
[0018] As mentioned above, the present invention thus relates to a composition, in particular a cosmetic composition, comprising, in a physiologically acceptable medium: i. at least one endolysin, in particular an endolysin derived from a Staphylococcus aureus phage; and ii. (ii) at least one polyvinyl alcohol (PVA).
[0019] As illustrated in the examples below, the Applicant has surprisingly discovered that a composition according to the invention, comprising an endolysin derived from a Staphylococcus aureus phage and at least one polyvinyl alcohol polymer, advantageously makes it possible to maintain the S. aureus destruction performance of the endolysin, even after a long period (for example 6 months).
[0020] Thus, the present invention also relates to the use of a composition of the invention for preventing and / or treating acne and / or eczema in an individual in need thereof.
[0021] The invention further relates to a non-therapeutic cosmetic process for caring for keratinous materials, in particular the skin, in particular skin prone to acne, comprising the topical application to these keratinous materials of a composition according to the invention. DETAILED DESCRIPTION
[0022] The term "cosmetic" designates a composition compatible with keratinous materials, in particular the skin, mucous membranes and integuments. The composition according to the invention is non-therapeutic.
[0023] The expression “keratinous materials” is intended to designate in particular the skin, mucous membranes, fibers, eyelashes and integuments.
[0024] The term "skin" designates all the skin of the body, and preferably the skin of the face, scalp, décolleté, neck, arms and forearms, eyelids, around the mouth or behind the ears, the hollow of the elbow, the back of the knees, hands, wrists and ankles, or even more preferably the skin of the face (in particular the forehead, nose, cheeks and chin), décolleté and neck.
[0025] A composition according to the invention comprises a physiologically acceptable medium, that is to say which has a pleasant color, odor and sensation and which does not give rise to any unacceptable discomfort, that is to say tingling, tightness or redness, likely to discourage the user from applying this composition. It goes without saying that the person skilled in the art will take care to choose a physiologically acceptable medium acceptable such that the advantageous properties of the endolysin(s) of the invention are not, or are not substantially, adversely affected. Thus, by way of illustration, a physiologically acceptable medium may consist mainly of water and / or one or more water-miscible organic solvents. A physiologically acceptable medium according to the invention preferably has a pH between 4 and 8, more particularly between 4.5 and 7.5. Thus, a composition according to the invention may comprise one or more pH correctors, for example arginine. According to a preferred embodiment, a composition according to the invention comprises at least one pH corrector, in particular a pH corrector, and in particular arginine.
[0026] As used herein, the terms "treat" and "treatment" refer to the alleviation of symptoms associated with a specific disorder or condition and / or the elimination of said symptoms and also the complete disappearance of the disorder or condition in question.
[0027] In the context of the present invention, the terms "prevent" and "prevention" designate the reduction to a lesser degree of the risk or probability of occurrence of a given phenomenon.
[0028] Endolysin
[0029] A composition, in particular a cosmetic composition, according to the invention is firstly characterized in that it comprises at least one endolysin.
[0030] In the embodiments herein, the endolysin may be a native bacteriophage endolysin or a recombinant endolysin and may be any endolysin known to those skilled in the art. Herein, the terms bacteriophage lysin, bacteriophage endolysin, and endolysin are used interchangeably. An endolysin may be selected from the group of endolysins defined in WO2011 / 023702, WO2012 / 146738, WO2003 / 082184, WO2010 / 011960, WO2010 / 149795, WO2010 / 149792, WO2012 / 094004, WO2011 / 023702, WO2011 / 065854, WO2011 / 076432, WO2011 / 134998, WO2012 / 059545, WO2012 / 085259, WO2012146738, WO2018 / 091707, Exebacase™ (Lysine CF-301); SAL200™ or Tonabacase; Auresine™ (Sigma-Aldrich SAE0083), and Ectolysin™ P128, which are incorporated herein in their entirety by reference.
[0031] In embodiments herein, the endolysin may be a Staphylococcus-specific endolysin, meaning that it will effectively lyse Staphylococcus, such as Staphylococcus aureus, but will not substantially lyse bacteria other than Staphylococcus or Staphylococcus aureus. In some embodiments, the endolysin will lyse Staphylococcus aureus, but not Staphylococcus epidermidis.
[0032] Most native Staphylococcus bacteriophage endolysins with peptidoglycan hydrolase activity, such as endolysin Ply2638, consist into a C-terminal cell wall-binding domain (CBD), a central N-acetylmuramoyl-L-Alanine amidase domain, and an N-terminal Alanyl-glycyl endopeptidase domain with cysteine homology, histidine-dependent amidohydrolases / peptidases (CHAP), or in the case of Ply2638, an N-terminal alanyl-glycine endopeptidase domain with peptidase_M23 homology, the latter three domains each exhibiting peptidoglycan hydrolase activity with distinct target binding specificity and generally referred to as enzymatically active domains.
[0033] The endolysin herein may be a recombinant endolysin, such as a Staphylococcus-specific recombinant endolysin, particularly a Staphylococcus-specific recombinant chimeric endolysin comprising one or more heterologous domains.
[0034] In general, endolysins are composed of different subunits (domains); for example: a cell wall binding domain (CBD) and one or more enzymatic domains having peptidoglycan activity, such as an amidase domain, an M23 domain and a CHAP (cysteine, histidine-dependent amidohydrolases / peptidases) domain. An example of a Staphylococcus-specific chimeric endolysin comprising one or more heterologous domains is an endolysin comprising a bacteriophage Ply2638 amidase domain, a lysostaphin (S. simulons) M23 domain and a bacteriophage Ply2638 cell wall binding domain.
[0035] This Staphylococcus-specific chimeric endolysin is a preferred endolysin and is described in detail in WO2012 / 150858, which is incorporated herein by reference in its entirety. Other preferred endolysins are described in detail in WO2013 / 169104, which is incorporated herein by reference in its entirety. Other preferred endolysins are described in detail in WO2016 / 142445, which is incorporated herein by reference in its entirety. Other preferred endolysins according to the invention are described in detail in WO2017 / 046021, which is incorporated herein by reference in its entirety.
[0036] In embodiments herein, the endolysin may comprise a domain having at least 80% sequence identity to a domain depicted in WO2012 / 150858, WO2013 / 169104, WO2016 / 142445, or WO2017 / 046021.
[0037] In embodiments herein, the endolysin may have at least 80% sequence identity with an endolysin shown in WO2012 / 150858, WO2013 / 169104, WO2016 / 142445, WO2017 / 046021, such as the endolysin with the amino acid as shown in SEQ ID NO: 29 in WO2012 / 150858.
[0038] According to a particular embodiment, the endolysin is an endolysin derived from a Staphylococcus aureus phage.
[0039] For the purposes of the present invention, "endolysin derived from a Staphylococcus aureus phage" means a native or recombinant protein such as an enzyme or a nucleic acid molecule encoding it derived from one or more bacteriophages capable of lysing the wall of bacteria of the species Staphylococcus aureus.
[0040] The endolysin comprises in particular one or more wall-binding domains Staphylococcus aureus bacterial cell wall and / or one or more Staphylococcus aureus bacterial cell wall lysis domains, said binding domain(s) and lysis domain(s) for the Staphylococcus aureus bacterial cell wall being derived from one or more identical or different bacteriophage(s) capable of lysing the bacterial cell wall of the species Staphylococcus aureus.
[0041] The endolysin used in the context of the present invention may be in the form native or recombinant, particularly in recombinant form.
[0042] According to a particular embodiment, the endolysin comprises a first protein sequence comprising a cell wall binding domain of species of the genus Staphylococcus.
[0043] In particular, the first protein sequence is derived from the endolysin of the bacteriophage <e>2638a of S. aureus.
[0044] For each of the amino acid or nucleic acid sequences of interest, reference sequences are described herein. The present disclosure also encompasses amino acid or nucleic acid sequences (e.g., enzyme amino acid sequences), having specific percentages of amino acid or nucleotide identity with a reference sequence.
[0045] For obvious reasons, throughout the present description, a specific nucleic acid sequence or a specific amino acid sequence that respects, respectively, the identity of the nucleotide or amino acid of interest, must also lead to the production of a protein (or enzyme) that displays the desired biological activity. As used herein, the "percent identity" between two nucleic acid sequences or between two amino acid sequences is determined by comparing the two optimally aligned sequences across a comparison window.
[0046] The portion of the nucleotide or amino acid sequence in the comparison window may thus include additions or deletions (for example: “deviations”) from the reference sequence (which does not include these additions or deletions) in order to obtain optimal alignment between the two sequences.
[0047] The terms "sequence homology" or "sequence identity" or "homology" or "identity" are used interchangeably herein. For the purposes of the invention, this means that to determine the percentage of sequence homology or sequence identity of two amino acid sequences or two sequences of nucleic acid, the sequences are aligned for optimal comparison. In order to optimize the alignment between the two sequences, gaps can be introduced into either of the two sequences being compared. This alignment can be performed over the entire length of the sequences being compared. The alignment can also be performed over a shorter length, for example, over approximately twenty, fifty, one hundred or more nucleic acids / bases or amino acids. Sequence identity is the percentage of identical matches between the two sequences over the reported aligned region.
[0048] Sequence comparison and determination of the percentage of sequence identity between two sequences can be performed using a mathematical algorithm. The person skilled in the art knows that several different computer programs are available for aligning two sequences and determining the identity between two sequences (Kruskal, JB (1983) An overview of sequence comparison in D. Sankoff and JB Kruskal, (ed.), Time warps, string edits and macromolecules: the theory and practice of sequence comparison, pages 1-44 Addison Wesley).
[0049] The percentage of sequence identity between two amino acid sequences or between two nucleotide sequences can be determined using the Needleman-Wunsch algorithm for the alignment of two sequences. (Needleman, SB and Wunsch, CD (1970) J. Mol. Biol. 48, 443-453). The algorithm allows the alignment of both amino acid sequences and nucleotide sequences. The Needleman-Wunsch algorithm has been implemented in the computer program NEEDLE.
[0050] For the purposes of the invention, the NEEDLE program of the EMBOSS software package was used (version 2.8.0 or higher, EMBOSS: The European Molecular Biology Open Software Suite (2000) Rice, P. Longden, J. and Bleasby, A. Trends in Genetics 16, (6) pages 276-277, http: / / emboss.bioinformatics.nl / ). For protein sequences, EBLOSUM62 is used for the substitution matrix. For nucleotide sequences, EDNAFULL is used. Optional parameters used are a gap opening penalty of 10 and a gap extension penalty of 0.5. No trailing gap penalty is added. In the Output section, Yes was indicated in response to the question "Brief identity and similarity" and "Pairwise SRS" was indicated as the output alignment format.
[0051] After alignment by the NEEDLE program described above, the percentage of sequence identity between a query sequence and a sequence of the invention is calculated as follows: Number of matching positions in the alignment showing an identical amino acid or nucleotide in both sequences divided by the total length of the alignment after subtracting the total number of gaps in the alignment. The identity defined here can be obtained by NEEDLE using the NOBRIEF option and is marked in the program output as "longest identity".
[0052] The similarity of nucleotide and amino acid sequences, i.e., the percentage identity of the sequences, can be determined by sequence alignments using several other known algorithms, preferably the mathematical algorithm of Karlin and Altschul (Karlin & Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5877), with hmmalign (HMMER software package, http: / / hmmer.wustl.edu / ) or with the CLUSTAL algorithm (Thompson, JD, Higgins, DG & Gibson, TJ (1994) Nucleic Acids Res. 22, 4673-80) available, for example, at https: / / www.ebi.ac.uk / Tools / msa / clustalo / or the GAP program (mathematical algorithm of the University of ITowa) or the mathematical algorithm of Myers and Miller (1989 - Cabios 4: 11-17) or Clone Manager 9. The preferred settings used are the default settings as defined at https: / / www.ebi.ac.uk / Tools / msa / clustalo / .
[0053] The degree of sequence identity (sequence match) can be calculated using, for example, BLAST, BLAT or BlastZ (or BlastX). A similar algorithm is incorporated in the BLASTN and BLASTP programs of Altschul et al. (1990) J. Mol. Biol., 215, 403-410. BLAST polynucleotide searches are performed with the BLASTN program, score = 100, word length = 12, so as to obtain polynucleotide sequences homologous to the nucleic acids that encode the protein of interest.
[0054] BLAST protein searches are performed with the program BLASTP, score = 50, word length = 3, to obtain amino acid sequences homologous to the SHC polypeptide. To obtain gapped alignments for comparison purposes, Gapped BLAST is used as described in Altschul et al. (1997) Nucleic Acids Res. 25, 3389-3402. When using the BLAST and Gapped BLAST programs, the default settings of the respective programs are used. Sequence concordance analysis can be complemented by established homology mapping techniques such as Shuffle-LAGAN (Brudno M., Bioinformatics 2003b, 19 Suppl. 1: 154-162) or Markov random fields. When reference is made to percentages of sequence identity in this patent application, such percentages are calculated relative to the total length of the longest sequence, unless otherwise indicated.
[0055] In particular embodiments, the percentage of identity between two sequences is determined using CLUSTAL O (version 1.2.4).
[0056] Thus, according to a particular embodiment, the first protein sequence comprises a protein sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with the reference amino acid sequence SEQ ID NO: 1.
[0057] The expression "at least 80% sequence identity between two sequences" means that the first sequence may comprise 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity with the second sequence, whether amino acid or nucleic acid sequences.
[0058] In particular, the first protein sequence consists of a reference amino acid sequence SEQ ID NO: 1.
[0059] The protein sequences described herein may be encoded by one or more allelic variants.
[0060] An allelic variant refers to one of two or more alternative forms of a gene occupying the same chromosomal locus. A preferred nucleic acid variant is a nucleotide sequence that contains one or more silent mutations. Alternatively or in combination, a nucleic acid variant may also be obtained by introducing nucleotide substitutions, which do not result in another amino acid sequence of the polypeptide encoded by the nucleotide sequence, but which correspond to the use of codons of the host organism intended for the production of the polypeptide of the invention. According to a preferred embodiment, a nucleic acid variant encodes a polypeptide still having its biological function. More preferably, a nucleotide sequence variant encodes a polypeptide exhibiting binding to the cell wall of species of the genus Staphylococcus and / or lytic activity.More preferably still, a nucleic acid variant encodes a polypeptide exhibiting increased binding to the cell wall of species of the genus Staphylococcus and / or lytic activity, as defined below. Nucleic acids encoding a polypeptide exhibiting binding to the cell wall of species of the genus Staphylococcus and / or lytic activity may be isolated from any microorganism.
[0061] All these variants can be obtained using techniques known to those skilled in the art, such as library screening by hybridization (Southern blot procedures) under low to medium to high hybridization conditions. The low to medium to high stringency conditions involve prehybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 pg / mL of sheared and denatured salmon sperm DNA, and 25%, 35% or 50% formamide for low to medium to high stringencies, respectively. Then, the hybridization reaction is washed three times for 30 minutes using for each wash 2XSSC, 0.2% SDS and at 55°C, 65°C or 75°C for low to medium to high stringencies.
[0062] According to a particular embodiment, the first protein sequence is encoded by a nucleic acid sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with the reference nucleic acid sequence SEQ ID NO: 2.
[0063] In particular, the first protein sequence is encoded by a nucleic acid sequence consisting of a reference nucleic acid sequence SEQ ID NO: 2.
[0064] Binding of a domain to the peptidoglycan cell wall of Staphylococcus genera can be assessed using assays well known to those skilled in the art. In a preferred embodiment, an immunohistochemical technique and / or a gene fusion technique resulting in labeled constructs of either domain are used to assess the specific binding of peptides, polypeptides or proteins to the peptidoglycan cell wall of Staphylococcus genera. The signal quantification processes used in the aforementioned immunohistochemical or fusion techniques are well known in the art.
[0065] In one embodiment, binding to the Staphylococcus peptidoglycan cell wall can be quantified using a fluorescent fusion construct comprising a polypeptide comprising a domain included in a first protein sequence as previously described. Such a cell wall binding assay is described in detail by Loessner et al. (Molecular Microbiology 2002, 44(2): 335-349). In said assay, a solution comprising said fluorescent fusion construct or a negative control, preferably green fluorescent protein (GFP), is subjected to Staphylococcus cells, preferably S. aureus cells, more preferably S. aureus BB255, for a specified period, after which the cells are pelleted by centrifugation with the bound fluorescent fusion constructs.The fluorescent signal of Staphylococcus cells exposed to a fluorescent fusion construct, subtracted from the fluorescent signal of Staphylococcus cells exposed to a negative control, preferably GPF, is a measure of cell binding for the purposes of the present invention.
[0066] Examples of evaluating the binding of an endolysin to the cell wall of species of the genus Staphylococcus suitable according to the invention are illustrated in particular in WO 2012 / 150858 A1.
[0067] Preferably, in the context of the present text, a protein sequence will be said to comprise a peptidoglycan cell wall binding domain of Staphylococcus genera when, using this assay, an increase in the fluorescent signal of the sedimented cells is detected. The binding is preferably said to be specific. Preferably, an endolysin comprising a domain is described which has a binding capacity, as defined herein, of at least 50, 60, 70, 80, 90 or 100, 150 or 200% of the peptidoglycan cell wall binding of the bacteriophage endolysin <e>2638a of S. aureus (Ply2638) encoded by the reference nucleic acid sequence SEQ ID NO: 5.
[0068] According to a particular embodiment, the cell wall binding activity of species of the genus Staphylococcus is measured by a technique immunohistochemical and / or a gene fusion technique, in particular a fluorescent fusion technique, more particularly fusion with a green fluorescent protein.
[0069] According to a particular embodiment, the endolysin comprises a protein sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with an amino acid sequence chosen from the group consisting of the amino acid sequences of the references SEQ ID NO: 3 and SEQ ID NO: 4.
[0070] According to a particular embodiment, the endolysin comprises a protein sequence encoded by a nucleic acid sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with the reference nucleic acid sequence SEQ ID NO: 5.
[0071] In particular, the protein sequence may be encoded by a nucleic acid sequence consisting of a reference nucleic acid sequence SEQ ID NO: 5.
[0072] According to a particular embodiment, the endolysin may also comprise a heterologous protein sequence.
[0073] The term "heterologous protein sequence" is intended to refer to a protein sequence, i.e., an amino acid sequence or a nucleic acid sequence encoding the protein sequence, which is not naturally functionally linked as a neighboring sequence to said first protein sequence. As used herein, the term "heterologous" may mean "recombinant." The term "recombinant" refers to a genetic entity different from that generally occurring in nature. When applied to a nucleotide sequence or nucleic acid molecule, it means that said nucleotide sequence or nucleic acid molecule is the product of various combinations of cloning, restriction and / or ligation steps, and other procedures that result in the production of a construct different from a sequence or molecule occurring in nature.
[0074] These methods of recombination of proteins or nucleic acids are well known to those skilled in the art.
[0075] According to a particular embodiment, the endolysin comprises a heterologous protein sequence comprising a lytic domain. Preferably, said lytic domain exhibits peptidoglycan hydrolase activity.
[0076] “Peptidoglycan hydrolase activity”, also defined herein as “activity lytic activity", can be assessed by methods well known to those skilled in the art. In one embodiment, the lytic activity can be assessed spectrophotometrically by measuring the decrease in turbidity of the substrate cell suspensions. Preferably, the lytic activity can be assessed spectrophotometrically by measuring the decrease in turbidity of a suspension of S. aureus, the turbidity being quantified by measuring the OD595 by spectrophotometry (Libra S22, Biochrom). More preferably, 200 nM of a polypeptide encoded by a nucleic acid molecule as identified herein is incubated with a suspension of S. aureus having an initial OD600 of 1 ± 0.05, as assessed by spectrophotometry (Libra S22, Biochrom), in PBS buffer pH 7.4, 120 mM sodium chloride for 30 min at 37 °C. The decrease in turbidity is calculated by subtracting the OD595 after 30 min of incubation from the OD595 before 30 min of incubation. In the context of this text, a protein sequence will be said to comprise a lytic domain when, using this assay, a decrease in turbidity of at least 10, 20, 30, 40, 50 or 60% is detected. Preferably, a decrease of at least 70% is detected.Preferably, there is described an endolysin comprising a domain which exhibits a lytic activity of at least 50, 60, 70, 80, 90, 100, 150 or 200% or more of a lytic activity of bacteriophage endolysin. <e>2638a of S. aureus (Ply2638) encoded by the reference nucleic acid sequence SEQ ID NO: 5.
[0077] According to a particular embodiment, the lytic activity of endolysin is measured by spectrophotometry by measuring the decrease in turbidity of a suspension of S. aureus.
[0078] In one embodiment, the endolysin is optionally not encoded by an amino acid sequence comprising or consisting of an amino acid sequence selected from the group consisting of the amino acid sequences of references SEQ ID NO: 3 and SEQ ID NO: 4.
[0079] In particular, the endolysin is optionally not encoded by a nucleic acid sequence comprising or consisting of the reference nucleic acid sequence SEQ ID NO: 5, encoding the bacteriophage endolysin ¢2638 of S. aureus.
[0080] According to a particular embodiment, the heterologous protein sequence comprises a lytic domain, said lytic domain comprising a second and a third protein sequence, said second protein sequence comprising an M23 endopeptidase domain and said third protein sequence comprising an amidase domain.
[0081] An endopeptidase domain as used herein preferentially cleaves pentaglycine cross-bridges (Trayer, HR and Buckley, CE (1970) Molecular properties of lysostaphin, a specific bacteriolytic agent for Staphylococcus aureus. J. Biol. Chem. 245, 4842-4846) which are found in the cell wall of Staphylococcus genera, preferably in the cell wall of S. aureus, S. simulons and S. camosus.
[0082] An amidase domain as used herein preferentially hydrolyzes gamma-glutamyl-containing substrates.
[0083] The functionality and activity of such domains in a polypeptide can be confirmed by characterizing the cleavage products upon incubation of said polypeptides containing one of these domains with a purified peptidoglycan.
[0084] According to a particular embodiment, the endopeptidase and / or amidase activity of endolysin is measured by characterizing the cleavage products.
[0085] According to a particular embodiment, the endopeptidase and / or amidase activity of endolysin can be measured by measuring the optical density of the bacteria in the presence of endolysin. These methods are notably described in Park et al. (Characterization of an endolysin, LysBPS13, from a Bacillus cereus bacteriophage, FEMS Microbiol. Lett. July 2012; 332(1): 76-83) and in Grishin et al. (A Simple Protocol for the Determination of Lysostaphin Enzymatic Activity, Antibiotics (Basel). Dec. 17, 2020; 9(12): 917).
[0086] Preferably, each of the protein sequences and nucleotide sequences encoding the second or third domain is of bacterial or bacteriophage origin.
[0087] According to a particular embodiment, said second and third protein sequences are derived, independently of one another, from an enzyme chosen from the group consisting of bacteriophage endolysin <e>2638a of S. aureus and lysostaphin of S. simulans. In particular, one of the second and third protein sequences is derived from bacteriophage endolysin <e>2638a of S. aureus and the other sequence of the second and third protein sequences is derived from lysostaphin of S. simulans.
[0088] According to a particular embodiment, said second protein sequence comprises at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with the reference amino acid sequence SEQ ID NO: 6 and said third protein sequence comprises at least 80%, in particular 90%, more particularly 95% sequence identity with the reference amino acid sequence SEQ ID NO: 8.
[0089] According to a particular embodiment, said second protein sequence is encoded by a nucleic acid sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with the reference nucleic acid sequence SEQ ID NO: 7 and said third protein sequence is encoded by a nucleic acid sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with the reference nucleic acid sequence SEQ ID NO: 9.
[0090] According to a particular embodiment, said second protein sequence is encoded by a nucleic acid sequence consisting of the reference nucleic acid sequence SEQ ID NO: 7 and said third protein sequence is encoded by a nucleic acid sequence consisting of the reference nucleic acid sequence SEQID NO: 9.
[0091] According to a particular embodiment, the endolysin comprises a protein sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with an amino acid sequence chosen from the group consisting of the amino acid sequences of the references SEQ ID NO: 10, and SEQ ID NO: 11.
[0092] In particular, the endolysin may comprise a protein sequence consisting of the reference amino acid sequence SEQ ID NO: 10.
[0093] According to a particular embodiment, the endolysin comprises a protein sequence encoded by a nucleic acid sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with a reference nucleic acid sequence SEQ ID NO: 12. In particular, the endolysin may comprise a protein sequence encoded by a nucleic acid sequence consisting of a reference nucleic acid sequence SEQ ID NO: 12.
[0094] An endolysin comprising a protein sequence encoded by a reference nucleic acid sequence SEQ ID NO: 12 differs from bacteriophage endolysin <t>2638a of S. aureus in that the N-terminal M23 endopeptidase domain is substituted by an M23 endopeptidase domain from S. simulons lysostaphin.
[0095] The endolysins suitable for use in the invention may be obtained by any method known to those skilled in the art for the production of recombinant proteins. In particular, the endolysins according to the invention may be obtained by introducing one or more genes of interest, such as the nucleic acid sequences described above, into the genome of a host organism via a vector.
[0096] In another aspect, a nucleic acid construct comprising at least one of the nucleic acid sequences as defined above is described. This nucleic acid construct may comprise a first nucleic acid sequence encoding a polypeptide comprising a cell wall binding domain, optionally also comprising a second and a third nucleic acid sequence as defined above.
[0097] An expression vector comprising such a nucleic acid construct is also disclosed. Preferably, an expression vector comprises a nucleotide sequence as mentioned above, which is operably linked to one or more control sequences, which direct the production or expression of the encoded polypeptide in a cell, subject or cell-free expression system.
[0098] An expression vector can be considered as a recombinant expression vector. This vector can consist of a plasmid, a cosmid, a bacteriophage or a virus which is transformed by the introduction of a nucleic acid molecule according to the invention. These transformation vectors depending on the host organism to be transformed are well known to those skilled in the art and widely described in the literature.
[0099] Another subject described herein is a process for transforming host organisms by the integration of at least one nucleic acid sequence as described, which transformation can be carried out by any suitable means known and widely described in the specialized literature, more particularly by means of the vector described above.
[0100] In another aspect, a cell is described which comprises a nucleic acid construct or an expression vector as defined above. A cell may be any microbial cell, prokaryotic or eukaryotic, which is suitable for expressing an endolysin which is suitable for use in the invention. In a preferred embodiment, said cell is an E. coli cell. In an even more preferred embodiment, said cell is E. coli CLlblue MRF.
[0101] The obtained endolysin can then be purified according to purification methods known in the art such as column chromatography, high performance liquid chromatography, etc.
[0102] In a particular embodiment, one or more of the protein sequences as defined in the text may comprise a sequence encoding a tag to facilitate purification of the resulting endolysin. Preferably, said tag is selected from, but not limited to, a group consisting of a FLAG tag, a poly(His) tag, an HA tag and a Myc tag. More preferably, said tag is a 6xHis tag. Even more preferably, said tag is an N-terminal 6xHis tag identical to SEQ ID NO: 13.
[0103] The endolysins which are suitable for use according to the invention and also the methods for producing them are described in particular in patent application WO 2012 / 150858 A1.
[0104] An endolysin derived from a Staphylococcus aureus phage which is suitable for use according to the invention may be present in the composition in freshly prepared form or in lyophilized form.
[0105] As used herein, the term "freshly prepared" is preferably defined as storage for no more than 2 days after production at 1.63 mg / mL in lyophilization buffer (50 mM Tris, 500 mM sucrose, 200 mM mannitol, 0.05% polysorbate 20 + 50% glycerol) at -20°C followed by thawing immediately prior to evaluation of lytic activity in an assay as identified herein.
[0106] The term "lyophilized" refers to an endolysin that has been dehydrated by lyophilization, which involves freezing the protein and then dehydrating it to remove the water.
[0107] After lyophilization, an endolysin in freeze-dried form may undergo a subsequent reconstitution step by adding water. In one embodiment, lyophilization and reconstitution may be performed by dialysis against three 300 mL aliquot changes of lyophilization buffer (50 mM phosphate or Tris, 500 mM sucrose, 200 mM mannitol, pH 7.4) and freezing in the gas phase of liquid nitrogen. Lyophilization may be performed under standard conditions, preferably at -40°C and under vacuum at 75 mTorr for 60 minutes, before increasing the temperature over 5 hours to -10°C and further increasing it over 60 minutes at -10°C at the same vacuum levels. As a final step, the temperature is preferably increased to 25°C over 10 hours. The samples are reconstituted by adding water.
[0108] A composition according to the invention may comprise a content of endolysin(s), in particular endolysin(s) derived from a Staphylococcus aureus phage, ranging from 0.0001% to 0.1% by weight relative to the total weight of the composition, in particular from 0.0005% to 0.01% by weight relative to the total weight of the composition, more particularly from 0.001% to 0.005% by weight relative to the total weight of the composition.
[0109] Polyvinyl alcohol type polymer
[0110] A composition according to the invention comprises at least one polyvinyl alcohol (PVA).
[0111] In particular, a PVA of a composition according to the invention includes at least units of formula (I):
[0112] [Formula I] --CH2—CHOH-- J 0
[0113] Said polyvinyl alcohol may be formed by polymerizing one or more vinyl ester monomers by bulk polymerization, solution polymerization, emulsion polymerization and suspension polymerization. The vinyl ester monomers may include various aliphatic acids, such as vinyl formate, vinyl acetate, vinyl butyrate, vinyl pivalate and vinyl versatate. The vinyl ester polymer thus obtained may be saponified to form a polyvinyl alcohol. The saponification (or hydrolysis) reaction can be total or partial.
[0114] Preferably, the polyvinyl alcohol used in the context of the present invention has a degree of hydrolysis ranging from 65% to 99%, more preferably ranging from 75% to 95%, better still ranging from 87% to 89%.
[0115] Preferably, the polyvinyl alcohol used in the context of the present invention has a degree of polymerization ranging from 100 to 2500, more preferably ranging from 200 to 1000, better still ranging from 300 to 600.
[0116] According to a particular embodiment, the polyvinyl alcohol has a mass average molecular weight of 1000 to 1,000,000 g / mol, preferably of 10,000 to 500,000 g / mol and even more preferably of 50,000 to 400,000 g / mol.
[0117] The PVA may advantageously be present in a composition according to the invention in a content which is usual for a cosmetic composition, in particular in a content which is usual for it to play its role as a film-forming and viscosity-controlling agent in a composition according to the invention, in particular in a cosmetic composition according to the invention, more particularly in a content which is usual for it to play its role as a film-forming and viscosity-controlling agent when it is the only film-forming and / or viscosity-controlling agent in a composition according to the invention.
[0118] A composition according to the invention may comprise a polyvinyl alcohol content ranging from 0.1% to 20% by weight relative to the total weight of the composition, in particular from 0.5% to 10%, even more preferably from 1% to 5% by weight relative to the total weight of the composition.
[0119] A composition according to the invention may comprise one or more endolysins according to the invention and one or more polyvinyl alcohols in an endolysin(s) / PVA mass ratio of between 0.0001 and 0.1 and in particular between 0.001 and 0.01.
[0120] A composition according to the invention may comprise a single type of polyvinyl alcohol or at least two or more polyvinyl alcohols.
[0121] Examples of polyvinyl alcohols which are suitable for use according to the invention are those sold under the names "Selvol® Ultalux FP" (a polyvinyl alcohol having a degree of polymerization of about 300 to 600 and a degree of hydrolysis of about 87 to 89), "Selvol® Ultalux FA" (a polyvinyl alcohol having a degree of polymerization of about 900 to 1500 and a degree of hydrolysis of about 87 to 89), "Selvol® Ultalux FF" (a polyvinyl alcohol having a degree of polymerization of about 1500 to 2500 and a degree of hydrolysis of about 87 to 89) and "SELVOL® 107" (a polyvinyl alcohol having a degree of polymerization of about 350 to 700 and a degree of hydrolysis of about 98 to 99) by the company Sekisui Specialty Chemicals®.
[0122] Additional ingredients
[0123] In addition to the above-mentioned compounds, a composition according to the invention may of course comprise one or more additional ingredients, other than a polyvinyl alcohol.
[0124] It goes without saying that the person skilled in the art will take care to choose this additional ingredient or ingredients in such a way that the advantageous properties of the endolysin or endolysins of the invention are not, or are not substantially, negatively affected.
[0125] The additional ingredients are present in the compositions in a content which is usual for each of them in a cosmetic composition, in particular in a content which is usual for each of them and which allows them to retain their cosmetic properties, more particularly in a content which is usual for each of them and which allows them, when they are each the only ingredient of a composition according to the invention having this property, to retain their cosmetic property.
[0126] Thus, a composition according to the invention may also comprise one or more of the ingredients, other than a PVA, chosen from surfactants; fatty substances; colorants; preservatives; perfumes; pH correctors such as organic acids such as citric acid; antioxidants; hydrophilic gelling agents such as hydroxypropylmethylcellulose; amino acids such as arginine; carbohydrates; chelating agents; sugar alcohols; cosmetic active agents; and mixtures thereof.
[0127] According to a particular embodiment, a composition according to the invention comprises less than 2% by weight, in particular less than 1% by weight, of hydroxypropylmethylcellulose relative to the total weight of the composition; more particularly, a composition according to the invention is free of hydroxypropylmethylcellulose.
[0128] A composition according to the invention may be presented in any form of presentation normally used in the cosmetic field.
[0129] It may in particular be in the form of an aqueous or aqueous-alcoholic solution, which may be gelled, a dispersion of the lotion type, which may be a two-phase dispersion, an oil-in-water or water-in-oil emulsion or a multiple emulsion, a gel, in particular an aqueous gel, or even a dispersion of oils in aqueous phase, in particular using spherules, these spherules being able to be polymeric particles or, better still, lipid vesicles of ionic and / or non-ionic type. In particular, a composition according to the invention may be in the form of a gel, in particular an aqueous gel. It may also be an anhydrous composition. The expression "anhydrous composition" designates a composition containing less than 10% by weight of water, in particular less than 5% by weight of water, more particularly less than 2% by weight of water or even less than 0.5% by weight of water, and in particular free of water, the water not being added during the preparation of the composition but corresponding to the residual water provided by the mixed ingredients. The composition may have a more or less fluid liquid consistency.
[0130] A composition according to the invention is preferentially suitable for topical administration.
[0131] Thus, a composition according to the invention can comprise all the constituents usually used in the topical application and administration envisaged.
[0132] A composition according to the invention may advantageously be in the form of an emulsion, obtained in particular by dispersing an aqueous phase in a fatty phase (W / O) or a fatty phase in an aqueous phase (O / W), of liquid or semi-liquid consistency of the milk type, or of soft consistency, or even of multiple emulsion (W / O / W or O / W / O). These compositions are prepared according to the usual known methods.
[0133] More particularly, a composition according to the invention may be intended for topical application and may preferably be in the form of an emulsion, preferably an oil-in-water emulsion. Preferably, such an emulsion is not intended to be rinsed after application.
[0134] A composition according to the invention is preferably intended to be applied to skin.
[0135] Preferably, the skin is the skin of the face, scalp, décolleté, neck, arms or forearms, or even more preferably the skin of the face (in particular the forehead, nose, cheeks, chin), décolleté and neck.
[0136] The composition may alternatively be in the form of a facial and / or body care or makeup product, and may be packaged, for example, as a cream in a jar or a fluid in a tube or a pump bottle or a dropper bottle.
[0137] The composition according to the invention can be manufactured by means of any known process generally used in the cosmetic field.
[0138] The ingredients are mixed before formation, in the order and under conditions easily determined by the person skilled in the art.
[0139] According to a particular embodiment of the invention, other agents intended to enhance the appearance and / or texture of the skin may also be added to the composition according to the invention.
[0140] Uses and processes
[0141] According to one of its aspects, the present invention relates to the cosmetic use, in particular the topical use, of a composition according to the invention for preventing and / or treating acne and / or eczema in an individual who needs it.
[0142] According to yet another of its aspects, the present invention relates to a non-therapeutic cosmetic process for caring for keratinous materials, in particular the skin, in particular skin prone to acne, comprising the topical application to these keratinous materials of a composition according to the invention.
[0143] A skin may in particular be skin having acne or at risk of having acne and / or skin having eczema or at risk of having eczema.
[0144] The cosmetic uses and processes considered according to the invention are non-therapeutic.
[0145] The cosmetic uses and processes of the invention are preferably carried out by topical administration of a composition according to the invention. As such, the composition of the cosmetic use is particularly suitable for topical administration.
[0146] Topical administration consists of the external application to the skin of cosmetic compositions according to the usual techniques for the use of these compositions.
[0147] By way of illustration, the cosmetic use or process according to the invention may be carried out by topical application, for example daily, of at least one composition according to the invention, which may be formulated, for example, in the form of a cream, a gel, a serum, a lotion, an emulsion or a cleansing milk, in particular in the form of a gel.
[0148] The application can be repeated for example 1 to 2 times per day over one day or more and generally over a prolonged period of at least 3 days, at least 1 week, at least 4 weeks, or even 4 to 15 weeks, with, where appropriate, one or more periods of interruption.
[0149] According to one embodiment, the application is daily (once a day) and generally over an extended period of at least 3 days, at least 1 week, at least 4 weeks or even 4 to 15 weeks, with one or more periods of interruption if necessary.
[0150] According to one embodiment, the cosmetic treatment process according to the invention may comprise a single application.
[0151] Throughout the description, including the claims, the expressions "between... and..." and "ranging from... to..." must be understood to mean inclusive limits, unless otherwise indicated.
[0152] The following examples illustrate the present invention without limiting its scope.
[0153] In the examples, unless otherwise indicated, the temperature is room temperature (20°C) and is expressed in degrees Celsius, and the pressure is atmospheric pressure. EXAMPLES
[0154] Protocol (experimental conditions)
[0155] Preparation of the working culture of Staphylococcus aureus
[0156] Preparation of the working suspension of Staphylococcus aureus (S. aureus) from an ATCC 6538 lyophilisate (according to the recommendations of standard NF EN 12353).
[0157] The lyophilisate is rehydrated in trypticase soy broth, plated on trypticase soy agar (TSA plates) and incubated for 24 hours at 32.5°C. The cells are then recovered and resuspended in a commercial cryoprotectant solution with cryobeads for storage at -80°C for up to 14 months (long-term storage strain).
[0158] From a cryoball of this strain at -80°C, a subculture is carried out on TSA agar slant which is then incubated for 24 hours at 32.5°C to obtain the stock culture. This stock culture is stored at 4°C for a maximum of 9 weeks. The working culture is obtained by subculturing the stock culture on trypticase soy agar and incubating it for 24 hours at 35°C. The working suspension is prepared by suspending the cells of this working culture in a tryptone salt diluent. This suspension is calibrated between 1 and 3x108 CFU (colony forming units) / mL by measuring the absorbance at 620 nm.
[0159]
[0160] Example 1
[0161] Evaluation of the antimicrobial activity of the samples against S. aureus
[0162] Six formulas were prepared according to the information given in Table 1 below. All formulas are aqueous mixtures, comprising a qsp quantity of water and also a preservative.
[0163] 1% hydroxypropylmethylcellulose (HPMC), used here for comparison, is in fact also a film-forming and / or viscosity-controlling polymer commonly used in the cosmetics industry.
[0164] At T0 months (i.e. between 1 and 7 days from the manufacture of the formulas) and T6 months from the manufacture of the formulas, aliquots of 20 grams of each formula are inoculated with 0.2 mL of a calibrated suspension of S. aureus. After homogenization, the microorganism content of the product represents a concentration of S. aureus of 106 CFU per gram of product, i.e. a 1% inoculation of a suspension of 108 CFU per mL (the inoculum content is determined by spreading the suspension onto trypticase soy agar plates and incubating for 24 hours at 35°C). After t = 30 minutes and t = 60 minutes of contact at room temperature (20°C ± 3°C), 1 gram of the mixture is weighed and 9.0 mL of Eugon Sup LT100 broth is then added, followed by mixing until completely homogenized. This mixture is then serially diluted in Eugon Sup LT 100 broth at 1 / 100.
[0165] Dilutions are plated on trypticase soy agar plates and incubated at 35°C for 48 hours until surviving S. aureus colonies are counted.
[0166] The antimicrobial activity on S. aureus is expressed as a logarithmic decrease compared to the initial content and associated with the activity of the active compound, which is the endolysin of the sequence SEQ ID NO: 10 by comparing the numbers of surviving S. aureus in the formulas with and without the endolysin of the sequence SEQ ID NO: 10, in the presence of each of the polymers under test.
[0167] This method is an adaptation of the challenge test method described in the standard “ISO 11930 Cosmetics - Microbiology - Evaluation of the antimicrobial protection of a cosmetic product”.
[0168] PVA and HPMC are present in the compositions of the present example in a usual content for each of them in a cosmetic composition, in particular in a usual content so that each of them plays its role as film-forming agent and / or viscosity control agent in a composition of the invention.
[0169] Results and conclusions
[0170] The results are expressed as a logarithmic decrease in Staphylococcus aureus compared to the inoculated content. The decreases are therefore between 0 log (no antimicrobial activity observed in the test, i.e. complete loss of endolysin activity of the sequence SEQ ID NO: 10) and -5.4 log (maximum reduction observable under the test conditions, i.e. maintenance of endolysin activity in the test). The test formula is therefore particularly active when the values are close to -5.4.
[0171] A first evaluation of the antimicrobial activity of endolysin is carried out at T0 (i.e. between 1 day and 7 days after the manufacture of the formulas), and a second at T6 months from the date of manufacture of the formulas. This evaluation is carried out on both occasions according to the protocol described above, i.e. a measurement of the activity of endolysin in the formula after 30 minutes of contact and 60 minutes of contact of S. aureus / formula.
[0172] The results are given in Table 1 below.
[0173] [Table 1] Table 1 INCI Name [C] (% by mass) Preservative PH [Endolysine of the sequence SE QID NO: 10] (% by mass) Challenge Test Results at T0 Stability of Challenge Test Results at T6M Reduction 1 og T30 min Reduction log T 1h Reduction log T30 min Reduction log T1h HPMC (Cellosiz e® E4M Premium from Dow) 1% 0.5% 7.2 0% 0 0 0 0 0.5% 7.2 0.002565% -5.1 -5.4 -0.2 -0.5 HPMC (Tylose ® MOBS 6 P4 from Shin-Etsu) 1% 0.5% 7.0 0% 0 0 0 0 0.5% 7.0 0.002565% -5.4 -5.4 -0.2 -0.3 Polyvinyl alcohol (INCI name: Polyvinyl alcohol) (Selvo1® Ultalu x FP from Sekisui Specialty Chemicals) 2% 0.5% 7.0 0% 0 0 0 0 0.5% 7.1 0.002565% -4.8 -5 -0.8 -1.7
[0174] The results show that the combination of PVA with endolysin of the sequence SEQ ID NO: 10 allows to maintain a better antibacterial performance against S. aureus of the endolysin - as shown by the Log reduction results in Table 1 - compared to the performance obtained by replacing PVA with HPMC.
[0175] Indeed, at T6M, the Log reductions are much higher with PVA than with the two different HPMC concentrations.
[0176] Example 2
[0177] Three compositions A to C were prepared according to the information and contents given in Table 2 below. Compositions A and B, outside the invention, comprise a gel base (water + preservative) and 1% hydroxypropylmethylcellulose (HPMC) (see Example 1). Composition C, according to the invention, comprises a gel base (water + preservative) and 2% PVA (see also Example 1). The contents are indicated as percentages in mass. 0.0025652% of the endolysin of the sequence SEQ ID NO: 10 was added to the compositions under a laminar flow hood to avoid any microbial contamination.
[0178] The preparation of the compositions depended on the desired viscosity of each.
[0179] Compositions A to C were prepared by adding 1.08 mL of an aqueous solution containing 0.095% by weight of endolysin of the sequence SEQ ID NO: 10 to 38.9 g of a gel base (water + preservative) in a 50 mL Falcon tube. The tube was placed in a shaker to homogenize the formulation at room temperature.
[0180] The compositions were prepared by mixing 1.08 mL of an aqueous solution containing 0.095% by weight of endolysin of the sequence SEQ ID NO: 10 with 38.9 g of a gel base using a mortar and pestle for 5 minutes. Samples of approximately 5 mL were aliquoted into 15 mL tubes and placed under storage conditions at 25°C, 40°C and 45°C.
[0181] A control formulation was prepared similarly to compositions A to C, using sterile storage buffer instead of endolysin (SB). Samples for viscosity measurements were also prepared in the same manner for a total volume of 50 mL using 1.35 mL of endolysin and 48.65 g of gel base in a Falcon tube.
[0182] The various polymers (PVA or HPMC) are present in the compositions of the present example in a usual content for each of them in a cosmetic composition, in particular in a usual content so that each of them plays its role as film-forming agent and viscosity control agent in a composition of the invention.
[0183] [Table 2] Table 2 INCI EU A 2% HPMC (outside the invention) B 1% HPMC (outside the invention) C 2% PVA (according to the invention) Preservative 0.51 0.51 0.51 Water 97.44 98.46 97.39 Hydroxypropyl methylcellulose (Cellosize Texture E4M PRM Hydroxypropyl Methylcellulose, from DOW) 2.06 / / Polyvinyl alcohol / / 2.1 (INCI name: Polyvinyl alcohol) (Selvol® Ultalux FP from Sekisui Specialty Chemicals) Hydroxypropyl methylcellulose (Tylose® MOBS 6 P4 from Shin-E tsu) / 1.03 /
[0184] A killing assay study was conducted on all the above compositions and also on the control composition with 2.7% by weight of an aqueous solution containing 0.095% by weight of endolysin of the sequence SEQ ID NO: 10 at T0 in order to measure the capacity of endolysin of the sequence SEQ ID NO: 10 to digest S. aureus. Only one concentration of S. aureus was used in this study and the OD600 was set at 0.15.
[0185] RESULTS AND CONCLUSIONS
[0186] In this study, a killing capacity greater than 90% or a log reduction of 1 was considered acceptable for formulations comprising endolysin of the sequence SEQ ID NO: 10. The results of this study are given in Table 3 below.
[0187] This study compares the evolution over time at T0 (i.e., between 1 day and 7 days after manufacturing the formulas), T7 (7 days after T0), T28 (28 days after T0), and T84 (84 days after T0) and temperature (at 25°C, 40°C, and 45°C) of the different compositions, observing the evolution of endolysin destruction values as a function of the values at T0 for all formulas. It also made it possible to highlight robust formulas (little or no change in endolysin stability over time) and less robust formulas (loss of endolysin destruction capacity over time) among the remaining formulas.
[0188] [Tables3] 25 °C 40 °C 45 °C T0 T7 T28 T84 T84 T84 A >90% >90% >90% >90% <90% <90% B >90% >90% >90% >90% <90% <90% C >90% >90% >90% >90% >90% >90%
[0189] The results of the study show that all compositions comprising endolysin of the sequence SEQ ID NO: 10 are stable at 25°C after three months of storage with a destruction dosage greater than 90%. After 84 days of storage at 40°C and 45°C, comparative formulas A and B show a reduction in activity antimicrobial activity of endolysin of the sequence SEQ ID NO: 10, as evidenced by the reduced degree of destruction.
[0190] Thus, it is clear that the systems according to the invention comprising an endolysin in combination with at least one PVA are robust systems for maintaining the antimicrobial activity against S. aureus of the endolysin of the sequence SEQ ID NO: 10 over time, in a cosmetic composition environment.
[0191] On the other hand, a system comprising an endolysin in combination with a film-forming and viscosity-controlling agent other than PVA, such as hydroxypropylmethylcellulose at a concentration equal to 1% or 2% by weight, shows a reduction in the antimicrobial activity of the endolysin of the sequence SEQ ID NO: 10 after 84 days at 40°C and 45°C. This system is therefore less resistant, particularly over time, than a system according to the invention.
[0192] List of sequences
[0193] SEQ ID NO: 1 CBD-2638 (protein)
[0194] WKQNKDGIWYKAEHASFTVTAPEGIITRYKGPWTGHPQAGVLQKGQTIKYD EQKFDGHVWVSWETFEGETVYMPVRTWDAKTGKVGKLWGEIK
[0195] SEQ ID NO: 2 CBD-2638 (nucleic acid)
[0196] TGGAAACAGAATAAAGATGGCATTTGGTATAAAG CTGAACATGCTTCGTTCACAGTGACAGCACCAGAGGGAATTATCCAAGAT ACAAAGGTCCTTGGACTGGTCACCCAAGCTGGTGTTACAAAAAAGGTC AAACGATTAAATATGATGAGGTTCAAAAATTTGACGGTCATGTTTGGGTAT CGTGGGAAACGTTTGAGGAGGACTGAGGAGGTTAT GCCGGTACGCACATGGGACGCTAAAACTGGTAAA GTTGGTAAGTTGTGGGGCGAAATTAAATAA
[0197] SEQ ID NO : 3 Ply2638 (protein)
[0198] MLTAIDYLTKKGWKISSDPRTYDGYPKNYGYRNY HENGINYDEFCGGYHRAFDVYSNETNDVPAVTSGTVIEANDYGNFGGTFVI RDANDNDWIYGHLQRGSMRFVVGDKVNQGDIIGLQGNSNYDNPMSWHLHL QLRPKDAKKDEKSQVCSGLAMEKYDITNLNAKQDKSKKKKHSKYSNVH IKGNKITAPPKPSIQGVVIHNDYGSMTPSQYLPWLYARENNGTHVNGWASVY ANRNEVLWYHPTDYVEWHCGNQWANANLIGFEVCESYPGRISDKLFLENEE ATLKVAADVMKSYGLPVNRNTVRLHNEFFGTSCPHRSWDLHVGKGEPYTTT NINKMKDYFIKRIKHYDGGKLEVSKAATIKQSDVKQEVKKQEAKQIVKAT DWKQNKDGIWYKAEHASFTVTAPEGIITRIKGPWTGHPQAGVLQKGQTIKY DEVQKFDGHVWVSWETFEGETVYMPVRTWDAKTVGKGKKKKK
[0199] SEQ ID NO : 4 Ply2638 (protein)
[0200] MRGSHHHHHHGSMLTAIDYLTKKGWKISSDPRTY DGYPKNYGYRNYHENGINYDEFCGGYHRAFDVYSNETNDVPAVTSGTVIEA NDYGNFGGTFVIRDANDNDWIYGHLQRGSMRFVVGDKVNQGDIIGLQGNSN YYDNPMSVHLQLRPKDAKKDEKSQVCSGLAMEKYDITNLNAKQDKSKNG SVKELKHIYSNHIKGNKITAPKPSIQGVVIHNDYGSQLQLQLYLPW NGTHVNGWASVYANRNEVLWYHPTDYVEWHCGNQ WANANLIGFEVCESYPGRISDKLFLENEEATLKVAADVMKSYGLPVNRNTV RLHNEFFGTSCPHRSWDLHVGKGEPYTTTNINKMKDYFIKRIKHYDGGKL EVSKAATIKQSDVKQEVKKQEAKQIVKATDWKQNKDGIWYKAEHASFTVTA PEGIITRYKGPWTGHPQAGVLQKGQTIKYDEVQKFDGHVWVSWETFEGETV YMPVRTWDACTGKVGKLWGEIK
[0201] SEQ ID NO : 5 Ply2638 (nucleic acid)
[0202] ATGCTAACTGCTATTGACTATCTTACGAAAAAAG GTTGGAAAATATCATCTGACCCTCGCACTTACGATGGTTACCCTAAAACT ACGGCTACAGAAATTACCATGAAAACGGCATTAA TTATGATGAGTTTTGTGGTGGTTATCATAGAGCTTTTGATGTTTACAGTAA CGAAACTAACGACGTGCCTGCTGTTACTAGCGGAACAGTTATTGAAGCAAA CGATTACGGTAATTTTGGTGGTACATTCGTTATTAGAGACGCTAACGATAA CGATTGGATATATGGGCATCTACAACGTGGCTCAATGCGATTTGTTGTAGG CGACAAAGTCAATCAAGGTGACATTATTGGTTTACAAGGTAATAGCAACTA TTACGACAATCCTATGAGTGTACATTTACATTTACAATTACGCCCTAAAGA CGCAAAGAAAGATGAAAAATCACAAGTATGTAGT GGTTTGGCTATGGAAATATGACATTACAAATTTAAATGCTAAACAAGAT AAATCAAAGAATGGGAGCGTGAAAGAGTTGAAAC ATATCTATTCAAACCATATTAAAGGTAACAAGATTACAGCACCAAAACCTA GTATTCAAGGTGTGGTCATCCACAATGATTATGGTAGTATGACACCTAGTC AATACTTACCATGGTTATATGCACGTGAGAATAACGGTACACACGTTAACG GTTGGGCTAGTGTTTATGCAAATAGAAACGAAGTGCTTTGGTATCATCCGA CAGACTACGTAGAGTGGCATTGTGGTAATCAATGGGCAAATGCTAACTTAA TCGGATTTGAAGTGTGTGAGTCGTATCCTGGTAGAATCTCGGACAAATTAT TCTTAGAAATGAAGAAGCGACATTGAAAGTAGC TGCGGATGTGATGAAGTCGTACGGATTACCAGTTAATCGCAACACTGTACG TCTGCATAACGAATTCTTCGGAACTTCTTGTCCACATCGTTCGTGGGACTT GCATGTTGGCAAAGGTGAGCCTTACACAACTACTAATATTAATAAAATGAA AGACTACTTCATCAAACGCATCAAACATTATTATGACGGTGGAAAGCTAGA AGTAAGCAAAGCACAACTATCAAACAATCTGAC GTTAAGCAAGAAGTTAAAAAGCAAGAAGCAAAAC AAATTGTGAAAGCAACAGATTGGAACAGAATAA AGATGGCATTTGGTATAAAGCTGAACATGCTTCGTTCACAGTGACAGCACC AGAGGGAATTATCACAAGATACAAAGGTCCTTGG ACTGGTCACCCACAAGCTGGTGTATTACAAAAAGGTCAAACGATTAAATAT GATGAGGTTCAAAATTTGACGGTCATGTTTGGGTATCGTGGGAAACGTTT GAGGGCGAAACTGTATACATGCCGGTACGCACAT GGGACGCTAAAACTGGTAAAGTTGGTAAGTTGTGGGGCGAAATTAAATAA
[0203] SEQ ID NO : 6 M23-LST (protein)
[0204] AATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYG VDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSK YNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLK SAGY
[0205] SEQ ID NO: 7 M23-LST (nucleic acid)
[0206] GCTGCAACACATGAACATTCAGCACAATGGTTGA ATAATTACAAAAAAGGATATGGTTACGGTCCTTATCCATTAGGTATAAATG GCGGTATGCACTACGGAGTTGATTTTTTTGAATATTGGAACACCAGTAA AAGCTATTTCAAGCGGAAAAATAGTTGAAGCTGG TTGGAGTAATTACGGAGGAGGTAATCAAATAGGTCTTATTGAAAATGATGG AGTGCATAGACAATGGTATATGCATCTAAGTAAATATAATGTTAAAGTAGG AGATTATGTCAAAGCTGGTCAAAATAATCGGTTGGTCTGGAAGCACTGGTTA TTCTACAGCACCATTTACATTGAATTCATTCATTCATTAAT TTCAACTGCCCAAGATCCAATGCCTTTCTTAAA GAGCGCAGGATAT
[0207] SEQ ID NO : 8 Ami-2638 (protein)
[0208] NKITAPKPSIQGVVIHNDYGSMTPSQYLPWLYARENNGTHVNGWASVYANR NEVLWYHPTDYVEWHCGNQWANANLIGFEVCESYPGRISDKLFLENEEATL QUAADVMKSYGLPVNRNTVRLHNEFFGTSCPHRSWDLHVGTGTTNKING KMKDYFIKRIKHYDG
[0209] SEQ ID NO : 9 Ami-2638 (nucleic acid)
[0210] GGTAACAAGATTACAGCACCAAAACCTAGTATTC AAGGTGTGGTCATCCACAATGATTATGGTAGTATGACACCTAGTCAATACT TACCATGGTTATATGCACGTGAGAATAACGGTACACACGTTAACGGTTGGG CTAGTGTTTATGCAAATAGAAACGAAGTGCTTTGGTATCATCCGACAGACT ACGTAGAGTGGCATTGTGGTAGCAATGGCAATCAAT TGCTAACTTAATCGGATTTGAAGTGTGTGAGTCGTATCCTGGTAGAATCTC GGACAAATTATTCTTAGAAAATGAAGAAGCGACA TTGAAAGTAGCTGCGGATGTGATGAAGTCGTACGGATTACCAGTTAATCGC AACACTGTACGTCTGCATAACGAATTCTTCGGAACTTCTTGTCCACATCGT TCGTGGGACTTGCATGTTGGCAAAGGTGAGCCTTACACAACTACTAATATT AATAAAATGAAAGACTACTTCATCAAACGCATCAAACATTATTATGACGGT
[0211] SEQ ID NO : 10 M23-LST Ami2638 CBD2638 (protéine)
[0212] AATHEHSAQWLNNYKKGYGYGPYPLGINGGMHYG VDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIENDGVHRQWYMHLSK YNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFSNSTAQDPMPFLK SAGYGKAGGTVTPTPNTGELLRPKDAKKDEKSQVCSGLAMEKYDITNLNAK QDKSKNGSVKELKHIYSNHIKGNKITAPKPSIQGVVIHNDYGSMTPSQYLP WLYARENNGTHVNGWASVYANRNEVLWYHPTDYV EWHCGNQWANANLIGFEVCESYPGRISDKLFLENEEATLKVAADVMKSYGL PVNRNTVRLHNEFFGTSCPHRSWDLHVGKGEPYTTTNINKMKDYFIKRIKH YYDGGKLEVSKAATIKQSDVKQEVKKQEAKQIVKATDWKQNKDGIWYKAEH ASFTVTAPEGIITRYKGPWTGHPQAGVLQKGQTIKYDEVQKFDGHVWVSWE TFEGETVYMPVRTWDAKTGKVGKLWGEIK
[0213] SEQ ID NO: 11 M23-LST Ami2638 CBD2638 (protein)
[0214] MRGSHHHHHHGSAATHEHSAQWLNNYKKGYGYGP YPLGINGGMHYGVDFFMNIGTPVKAISSGKIVEAGWSNYGGGNQIGLIEND GVHRQWYMHLSKYNVKVGDYVKAGQIIGWSGSTGYSTAPHLHFQRMVNSFS NSTAQDPMPFLKSAGYGKAGGTVTPTPNTGELLRPKDAKKDEKSQVCSGLA MEKYDITNLNAKQDKSKNGSVKELKHIYSNHIKGNKITAPKPSIQGVVIHN DYGSMTPSQYLPWLYARENNGTHVNGWASVYANR NEVLWYHPTDYVEWHCGNQWANANLIGFEVCESYPGRISDKLFLENEEATL KVAADVMKSYGLPVNRNTVRLHNEFFGTSCPHRSWDLHVGKGEPYTTTNIN KMKDYFIKRIKHYYDGGKLEVSKAATIKQSDVKQEVKKQEAKQIVKATDWK QNKDGIWYKAEHASFTVTAPEGIITRYKGPWTGHPQAGVLQKGQTIKYDEV QKFDGHVWVSWETFEGETVYMPVRTWDAKTGKVGKLWGEIK
[0215] SEQ ID NO: 12 M23-LST Ami2638 CBD2638 (nucleic acid)
[0216] GCTGCAACAC ATGAAC ATTCAGC ACAATGGTTGA ATAATTACAAAAAAGGATATGGTTACGGTCCTTATCCATTAGGTATAAATG GCGGTATGCACTACGGAGTTGATTTTTTTTATGAATATTGGAACACCAGTAA AAGCTATTTCAAGCGGAAAAATAGTTGAAGCTGG TTGGAGTAATTACGGAGGAGGTAATCAAATAGGTCTTATTGAAAATGATGG AGTGCATAGACAATGGTATATGCATCTAAGTAAATATAATGTTAAAGTAGG AGATTATGTCAAAGCTGGTCAAATAATCGGTTGGTCTGGAAGCACTGGTTA TTCTACAGCACCACATTTACACTTCCAAAGAATGGTTAATTCATTTTCAAA TTCAACTGCCCAAGATCCAATGCCTTTCTTAAAGAGCGCAGGATATGGAAA AGCAGGTGGTACAGTAACTCCAACGCCGAATACAGGTGAGCTCTTACGCCC TAAAGACGCAAAGAAAGATGAAAAATCACAAGTA TGTAGTGGTTTGGCTATGGAAAAATATGACATTACAAATTTAAATGCTAAA CAAGATAAATCAAAGAATGGGAGCGTGAAAGAGT TGAAACATATCTATTCAAACCATATTAAAGGTAACAAGATTACAGCACCAA AACCTAGTATTCAAGGTGTGGTCATCCACAATGATTATGGTAGTATGACAC CTAGTCAATACTTACCATGGTTATATGCACGTGAGAATAACGGTACACACG TTAACGGTTGGGCTAGTGTTTATGCAAATAGAAACGAAGTGCTTTGGTATC ATCCGACAGACTACGTAGAGTGGCATTGTGGTAATCAATGGGCAAATGCTA ACTTAATCGGATTTGAAGTGTGTGAGTCGTATCCTGGTAGAATCTCGGACA AATTATTCTTAGAAAATGAAGAAGCGACATTGAA AGTAGCTGCGGATGTGATGAAGTCGTACGGATTACCAGTTAATCGCAACAC TGTACGTCTGCATAACGAATTCTTCGGAACTTCTTGTCCACATCGGTTCGTG GGACTTGCATGTTGGCAAAGGTGAGCCTTACAACTACTATATTAATAA AATGAAAGACTACTTCATCAAACTACCATCATTGATTGAGGAATGATTCTT GCTAGAAGTAAGCAAAGCAGCAACTATCAAACAA TCTGACGTTAAGCAAGAAGTTAAAAAGCAAGAAG CAAAACAAATGTGAAAGCAACAGATTGGAAACA GAATAAAGATGGCATTTGGTATAAAGCTGAACATGCTTCGTTCACAGTGAC AGCACCAGAGGGAATTATCCAAGATACAAAGGT CCTTGGACTGGTCACCCACAAGCTGGTGTTACAAAAAAGGTCAAACGATT AAAATATGATGAGGTTCAAAAATTTGACGGTCATGTTTGGGTATCGTGGGAA ACGTTTGAGGGCGAAACTGTATACATGCCGGTAC GCACATGGGACGCTAACTGAGTAAAGTTGAGTTGAGGAGAGAGAGAGA
[0217] SEQ ID NO : 13 6xHis N-terminal tag
[0218] MRGSHHHHHHGS< / t> < / e> < / e> < / e> < / e> < / e>
Claims
Claims
1. Composition, in particular cosmetic composition, comprising, in a physiologically acceptable medium: (i) at least one endolysin; and (ii) at least one polyvinyl alcohol.
2. The composition of claim 1, wherein the endolysin is an endolysin derived from a Staphylococcus aureus phage.
3. A composition according to any one of claims 1 to 2, wherein the endolysin comprises a protein sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with an amino acid sequence selected from the group consisting of the amino acid sequences of references SEQ ID NO: 3 and SEQ ID NO:
4.
4. A composition according to any one of claims 1 to 3, wherein the endolysin comprises a protein sequence comprising at least 80%, in particular at least 90%, more particularly at least 95% sequence identity with an amino acid sequence selected from the group consisting of the amino acid sequences of references SEQ ID NO: 10, and SEQ ID NO: 11, in particular the endolysin comprises a protein sequence consisting of the reference amino acid sequence SEQ ID NO:
10.
5. A composition according to any one of claims 1 to 4, wherein the endolysin, in particular endolysin derived from a Staphylococcus aureus phage, is present in an amount ranging from 0.0001% to 0.1% by weight, in particular from 0.0005% to 0.01% by weight, more particularly from 0.001% to 0.005% by weight relative to the total weight of the composition.
6. Composition according to any one of claims 1 to 5, the polyvinyl alcohol including at least one of the units of formula (I):
7. A composition according to any one of claims 1 to 6, wherein the polyvinyl alcohol has a mass average molecular weight of 1000 to 1,000,000 g / mol, preferably 10,000 to 500,000 g / mol and even more preferably 50,000 to 400,000 g / mol.
8. Composition according to any one of claims 1 to 7, in which the polyvinyl alcohol is present in a content ranging from 0.1% to 20% by weight relative to the total weight of the composition, in particular from 0.5% to 10%, even more preferably from 1% to 5% by weight relative to the total weight of the composition.
9. A composition according to any one of claims 1 to 8, the composition being suitable for topical administration.
10. Composition for use, in particular topical use, according to any one of claims 1 to 9, for preventing and / or treating acne and / or eczema in an individual in need thereof.
Citation Information
Patent Citations
Truncated lysostaphin molecule with enhanced staphylolytic activity
WO2003082184A2
Triple acting antimicrobials that are refractory to resistance development
WO2010011960A2
Antimicrobial agents
WO2010149792A2
Antimicrobial agents
WO2010149795A1
New endolysin obpgplys
WO2011023702A1
